CC-11050: Clinical Trials

3 trials of CC-11050, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 unknown, 1 completed. 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 23Unknown 2, Completed 1

Follow CC-11050: new trials by email Literature Review of CC-11050 trials Research Report on CC-11050

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
CC-11050 Trial in Nepalese Patients With Erythema Nodosum Leprosum
CC-11050 - Erythema Nodosum Leprosum, Leprosy
Phase 2UnknownThe Leprosy Mission Nepal502018-01-072020-07-07
TB Host Directed Therapy
Everolimus 0.5 MG, Auranofin 6 MG, Vitamin D3 - Tuberculosis
Phase 2UnknownThe Aurum Institute NPC2002016-11-012019-01-10
To Evaluate the Preliminary Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CC-11050 in Subjects With Discoid Lupus Erythematosus and Subacute Cutaneous Lupus Erythematosus
CC-11050, Placebo - Cutaneous Lupus Erythematosus
Phase 2CompletedAmgen482010-10-012020-06-23

Conditions studied

Leprosy (1)  ·  Lupus Erythematosus, Cutaneous (1)  ·  Lupus Erythematosus, Discoid (1)  ·  Tuberculosis (1)

Sponsors

Amgen (1)  ·  The Aurum Institute NPC (1)  ·  The Leprosy Mission Nepal (1)

Countries

Nepal (1)  ·  South Africa (1)  ·  United States (1)

Top investigators

Mahesh Shah, MD (1)  ·  Robert S Wallis, MD,FIDSA (1)

Results publications

PMID 33740465, PMID 42308518